← Eichor
Condition: Locally Advanced Malignant Solid Neoplasm Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Locally Advanced Malignant Solid Neoplasm

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Clinical Trial to Evaluate Effect of IBB0979 in Patients With Advanced Malignant Tumors
Phase 1/Phase 2 · 1 location(s) · SUNHO（China）BioPharmaceutical CO., Ltd. · NCT05991583A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of
Phase 1/Phase 2 · 12 location(s) · Ipsen · NCT07213817A Study of RC118 in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors
Phase 1/Phase 2 · 2 location(s) · RemeGen Co., Ltd. · NCT05205850A Study of RC148 As a Single Agent and Combination Therapy in Patients with Locally Advanced Unresectable or Metastatic
Phase 1/Phase 2 · 31 location(s) · RemeGen Co., Ltd. · NCT06016062A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
Phase 1 · 21 location(s) · Nuvalent Inc. · NCT06521554First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
Phase 1 · 10 location(s) · Plexium, Inc. · NCT07284186Study of IBI3005 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors
Phase 1 · 1 location(s) · Innovent Biologics (Suzhou) Co. Ltd. · NCT06418061Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
Phase 1/Phase 2 · 26 location(s) · Tango Therapeutics, Inc. · NCT05732831Imaging of Solid Tumors Using 18F-TRX
Phase 1 · 1 location(s) · Rahul Aggarwal · NCT06942104A Study With ABL103 in Subjects With Advanced or Metastatic Solid Tumors
Phase 1 · 3 location(s) · ABL Bio, Inc. · NCT06126666Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors
Phase 1/Phase 2 · 3 location(s) · National Cancer Institute (NCI) · NCT05053971Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or G
Phase 1 · 1 location(s) · Roswell Park Cancer Institute · NCT04511039Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment
Phase 2 · 7 location(s) · Centre Leon Berard · NCT02029001Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT03907475A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Ac
Phase 1/Phase 2 · 74 location(s) · Nuvalent Inc. · NCT05384626A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (A
Phase 1/Phase 2 · 63 location(s) · Nuvalent Inc. · NCT05118789Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Phase 1 · 30 location(s) · Calico Life Sciences LLC · NCT04777994Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients Wi
Phase 1 · 1 location(s) · National Cancer Institute (NCI) · NCT06364410A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity
Phase 1/Phase 2 · 11 location(s) · Ipsen · NCT07213830A Study of AP402 in HER2-Positive Patients With Locally or Advanced Solid Tumors
Phase 1/Phase 2 · 3 location(s) · AP Biosciences Inc. · NCT06669975A Study of TAK-505 in Adults With Solid Tumors
Phase 1/Phase 2 · 15 location(s) · Takeda · NCT07436728Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT04879121Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
Phase 1 · 18 location(s) · MOMA Therapeutics · NCT06545942Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The Co
Phase 2 · 483 location(s) · National Cancer Institute (NCI) · NCT05564377Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types
Phase N/A · 1 location(s) · Mayo Clinic · NCT06075524ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (
Phase 1 · 9 location(s) · Acepodia Biotech, Inc. · NCT06415487Topical Tretinoin Prophylaxis for Anti-EGFR Induced Skin Toxicity in Patients With Solid Tumors
Phase 2 · 1 location(s) · University of Utah · NCT06358677A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer
Phase 1/Phase 2 · 2 location(s) · Spago Nanomedical AB · NCT06184035XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.
Phase 1/Phase 2 · 1 location(s) · Evopoint Biosciences Inc. · NCT06792435Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Neg
Phase 1 · 1 location(s) · Fred Hutchinson Cancer Center · NCT05098210
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.